In a statement released on its official website and X handle, NAFDAC declared that these products are prohibited from manufacture, importation, exportation, distribution, advertisement, sale, and use across the country due to regulatory and safety issues.

The agency outlined three categories of regulatory actions: withdrawal, where the Market Authorisation Holder voluntarily discontinues a product’s registration; suspension, when the original licensing conditions are no longer met, pending further review; and cancellation, where NAFDAC revokes the product’s registration license outright. 

The full list of affected products, including medications like Abacavir Sulfate/Lamivudine Dispersible Tablets and Amaryl M Tablets, is available on NAFDAC’s GreenBook portal for public reference.(bit.ly/4pylYtQ)

NAFDAC’s Director-General, Prof. Mojisola Adeyeye, emphasized that the decision aligns with the agency’s mandate to safeguard public health under the Renewed Hope Agenda. 

“These measures are critical to eliminating substandard and falsified products from circulation,” she stated, urging healthcare providers, distributors, and consumers to cease using the listed items and report violations. 

The announcement follows recent enforcement actions, including the agency’s raid on an illegal cosmetics factory in a military mammy market, underscoring its intensified efforts to combat unsafe products.